CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...

Regeneron Pharmaceuticals just belly-flopped into a fresh 12-month low, trading as low as $640.28—Wall Street winced. Analyst ...

American Century Companies trimmed its stake in Regeneron Pharmaceuticals by 4.2% during Q4, selling nearly 31,000 shares and ...

Regeneron Pharmaceuticals Inc. closed 47.64% short of its 52-week high of $1,211.20, which the company reached on August 27th.

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer discussed recently. Jim Cramer kicked off his latest ...

This was the stock's third consecutive day of losses.

TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries (TA:TEVA) reported a slightly smaller-than-expected fall in ...

By Manojna Maddipatla (Reuters) - The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc (O:REGN) ...